Production (Stage)
Rapid Dose Therapeutics Corp.
RDTCF
$0.1393
-$0.0407-22.61%
OTC PK
| 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | |
|---|---|---|---|---|---|
| Revenue | 98.28% | 51.97% | 18.54% | 30.44% | 40.22% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 98.28% | 51.97% | 18.54% | 30.44% | 40.22% |
| Cost of Revenue | 106.51% | 18.59% | 0.34% | -2.87% | 16.08% |
| Gross Profit | 92.43% | 87.71% | 34.02% | 64.41% | 64.50% |
| SG&A Expenses | 98.49% | 64.53% | 47.03% | 9.94% | -25.80% |
| Depreciation & Amortization | -63.68% | -46.49% | -28.28% | -12.09% | 1.05% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 54.71% | 40.19% | 34.31% | 13.79% | -10.16% |
| Operating Income | -39.40% | -35.96% | -40.98% | -8.93% | 20.23% |
| Income Before Tax | -21.13% | -60.18% | -67.98% | -47.17% | -10.74% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -21.13% | -60.18% | -67.98% | -47.17% | -10.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.13% | -60.18% | -67.98% | -47.17% | -10.74% |
| EBIT | -39.40% | -35.96% | -40.98% | -8.93% | 20.23% |
| EBITDA | -63.75% | -63.48% | -59.58% | -9.78% | 28.52% |
| EPS Basic | -3.97% | -40.63% | -53.51% | -38.52% | -7.47% |
| Normalized Basic EPS | -19.51% | -26.42% | -36.62% | -22.37% | 6.29% |
| EPS Diluted | -3.97% | -40.63% | -53.51% | -38.52% | -7.47% |
| Normalized Diluted EPS | -19.51% | -26.42% | -36.62% | -22.37% | 6.29% |
| Average Basic Shares Outstanding | 17.78% | 15.68% | 10.65% | 6.01% | 1.65% |
| Average Diluted Shares Outstanding | 17.78% | 15.68% | 10.65% | 6.01% | 1.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |